Feb 01,2017

Performance of the FreeStyle Libre Flash glucose monitoring system in patients with type 1 and 2 diabetes mellitus

The research aims to evaluate the performance of the FreeStyle Libre Flash continuous glucose monitoring (FSL-CGM) system against established central laboratory methods. 20 subjects (8 type 1 diabetes mellitus, 12 type 2 diabetes mellitus) were analyzed. FSL-CGM sensor measurements (inserted in arm and abdomen) were compared with capillary blood glucose results analyzed with StatStrip as semigold standard. The glucose response after a standardized oral glucose load was measured by FSL-CGM and capillary samples analyzed by perchloric acid hexokinase (PCA-HK) method, StatStrip and FSL test strip (FSLC), and a commonly used CGM system (iPro2).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 01,2017

Willingness of patients with diabetes to use an ICT-based self-management tool: a cross-sectional study

The reserach aims to examine the prevalence of the willingness of patients with diabetes to use a self-management tool based on information and communication technology (ICT) such as personal computers, smartphones, and mobile phones; and to examine the patient characteristics associated with that willingness.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 02,2017

BD Announces Results For 2017 First Fiscal Quarter

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.922 billion for the first fiscal quarter ended December 31, 2016. This represents a decrease of 2.1 percent from the prior-year period revenues due to the divestiture of the Respiratory Solutions business that was completed in October 2016. On a comparable, currency-neutral basis, first quarter revenues grew 6.1 percent.

View Analyst & Ambassador Comments
Go to original news
Feb 13,2017

Insulet Corporation to Present at Upcoming Investor Conferences

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at two upcoming investor conferences: The Cowen and Company 37th Annual Health Care Conference in Boston, Massachusetts on Monday, March 6, 2017 at 2:00pm (Eastern Time), and The Raymond James 38th Annual Institutional Investors Conference in Orlando, Florida on Tuesday, March 7, 2017 at 11:35am (Eastern Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 15,2017

Roche Diabetes Care and mySugr expand their partnership to broaden access to digital health solutions for people with diabetes

Roche today announced the expansion of its partnership with mySugr, a digital diabetes service company providing apps to help reduce the burden for people with diabetes in managing their chronic condition. The integration of Roche’s next generation of Accu-Chek blood glucose meters, the Accu-Chek Guide and the Accu-Chek Instant systems with the mySugr app allows users to benefit from the partnership in different ways: The ability to automatically upload blood glucose data into the mySugr app as well as the facilitated data sharing with healthcare professionals and caregivers via the cloudbased Accu-Chek Connect Online and emminens eConecta platforms.

COLLABORATION PARTNERSHIP

#connected device

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 15,2017

Roche Diabetes Care presents innovative monitoring and digital health solutions to support improved outcomes and true relief

At Roche Diabetes Care’s media event on the occasion of the 10th annual meeting of the Association for Advanced Technologies & Treatments for Diabetes (ATTD) in Paris, France, latest integrated digital health solutions and new monitoring technologies were presented. Experts discoursed how new digital health solutions and innovations like Accu-Chek Guide, Accu-Chek Insight CGM or Senseonics’ Eversense system Roche is distributing in numerous markets can improve therapy routines and results.

View Analyst & Ambassador Comments
Go to original news
Feb 15,2017

Nemaura Medical Inc., to present sugarBEAT® Poster at the Advanced Technologies and Treatments for Diabetes Symposium (ATTD) in Paris, February 16th 2017

The poster will illustrate sugarBEAT®’s miniaturized wireless format, as a discreet coin sized oval device less than 10mm in height, and also showcase the sugarBEAT® mobile phone application which is designed to display blood glucose readings at any point in time and provide summary ambulatory glucose profiles (AGP).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 15,2017

Data Presented at ATTD 2017 Demonstrate Clinical Advantages of Tandem Diabetes Care Sensor-augmented Pump (SAP) over Medtronic MiniMed SAPs

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today presented study results comparing retrospective user data from sensor-augmented pumps (SAPs) made by Tandem Diabetes Care and Medtronic Minimed®. SAPs receive continuous glucose monitoring (CGM) data from a wearable sensor. The Tandem SAP demonstrated statistically significant clinical advantages, including reduced hypoglycemia, increased time in range, and improved overall glycemic control, despite approximately half of Medtronic SAP users actively using a feature that suspends insulin delivery if blood glucose falls below a preset threshold.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Feb 15,2017

Roche Diabetes Care Signs Exclusive Agreement with Medtronic for Bluetooth Enabled Blood Glucose Meters

Roche today announced that it has signed an exclusive partnership agreement with Medtronic plc. Under the terms of the agreement, Roche will develop a dedicated Bluetooth Low Energy (BLE) enabled blood glucose monitoring meter that will communicate with Medtronic’s future BLE enabled insulin pump systems. The new meter will be based on Roche’s innovative Accu-Chek Guide platform and will be marketed under the name Accu-Chek Guide Link. The exclusive agreement covers all markets where future BLE enabled pumps will be commercialized.

COLLABORATION PARTNERSHIP

#connected device

#bgm

View Analyst & Ambassador Comments
Go to original news
Feb 16,2017

ASCENSIA DIABETES CARE PRESENTS KEY ACCURACY DATA AT ATTD 2017

At the 10th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), Ascensia Diabetes Care presented data from four scientific posters. Three of these posters provided further evidence for the high levels of accuracy of the CONTOUR®NEXT ONE and CONTOUR®PLUS ONE blood glucose monitoring systems (BGMSs), including evidence to show that the CONTOUR®NEXT ONE meets the tightened accuracy requirements of the FDA Over-the-Counter BGMS Guidance recently issued in 2016. The fourth poster presented a new methodology for revealing the differences between multiple BGMSs that meet EN ISO 15197:2015 (ISO 15197:2013) accuracy criteria. The ATTD 2017 began yesterday in Paris, France and continues through February 18, 2017.

CLINICAL STUDY

#bgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES